

DAFTAR PUSTAKA

- Abbas AK, Lichtman AH, Pillai S (2018). Cellular and Molecular Immunology. 9th ed. Philadelphia: Elsevier.
- Aggarwal, B.B. (2019) “*Signaling pathways of the TNF superfamily: A double-edged sword in health and disease*”, *Journal of Clinical Investigation*, 129(1), pp. 14–28.
- Agustiantwo, R.A.P. (2024) ‘The role of innate immunity against *Mycobacterium leprae*: a systematic literature review’, *Scientific Journal of Dermatology and Venereology*, 2(1), pp. 31–37.
- Andrade, P.R., Pinheiro, R.O., Sales, A.M., Illarramendi, X., Nery, J.A.C. and Sarno, E.N. (2015) *Early diagnosis and treatment strategies in leprosy: An overview*. Clinics in Dermatology, 33(1), pp. 21–28.
- Antunes, D.E., Santos, D.F., Lima, M.I.S., Caixeta, L.P., Correa, M.B.C., Moraes, E.C.S., Conceição, N.C.A., Goulart, L.R. & Goulart, I.M.B. (2022) ‘Clinical, epidemiological, and laboratory prognostic factors in patients with leprosy reactions: A 10-year retrospective cohort study’, *Frontiers in Medicine*, 9, 841030.
- Apriano, A., Widodo, S. and Rahmadani, N. (2024). Bacterial load as a key determinant in the severity of erythema nodosum leprosum among multibacillary patients. *Asian Journal of Tropical Clinical Immunology*, 9(1), pp.12–20.
- Bhat, R. M., & Vaidya, T. P. (2020). What is New in the Pathogenesis and Management of Erythema Nodosum Leprosum. In *Indian Dermatology Online Journal* (Vol. 11, Issue 4, pp. 482–492). Wolters Kluwer Medknow Publications.
- Bhushan, P., Kumar, A., Verma, S. and Singh, P. (2018). Comparative genomics of *Mycobacterium leprae*: insights into reductive evolution and pseudogene formation. *Infection, Genetics and Evolution*, 58, pp. 124–132.
- Butlin, C.R., Darlong, J. & Mukhier, M. (2023) ‘Access to thalidomide’, *Leprosy Review*, 94(3), pp. 186–192.
- Cabral, P.B., da Silva, M.B., de Macedo, C.S., Lara, F.A. and Cole, S.T. (2022). Schwann cell–*Mycobacterium leprae* interactions: implications for nerve damage in leprosy, *PLoS Neglected Tropical Diseases*, 16(3), e0010203.
- Chatterjee, D., Saikia, U.N., Narang, T. & Dogra, S. (2017) ‘Histological spectrum of pure neuritic leprosy with atypical clinical presentation at a tertiary care centre’, *Leprosy Review*, 88(4), pp. 478–487.
- Chen, K.-H., Lee, Y.-C., Huang, M.-T., Wang, S.-L. and Lin, P.-H. (2022) ‘Clinical characteristics and epidemiological trends of leprosy: A population-based study’, *Journal of Dermatological Research*, 18(4), pp. 221–229.
- Citrashanty, I., Agusni, I., Sjamsoe-Daili, E. and Muliarto, R. (2014) ‘Serum tumour necrosis factor- α levels in patients with erythema nodosum leprosum before and after corticosteroid therapy’, *Leprosy Review*, 85(2), pp. 120–126.
- Claudio, N., Patricia, M., Andrea, L. and Sergio, A. (2017). Genomic decay and functional reduction in *Mycobacterium leprae*: evolutionary perspectives. *Journal of Bacteriology*, 199(5), pp. 1–12.

- Cogen, A.L., Nizet, V. and Gallo, R.L. (2020) ‘Skin microbiota: a source of disease or defence?’, *British Journal of Dermatology*, 182(5), pp. 1120–1128.
- Costa MB, Hungria EM, Freitas AA, Oliveira RM, Antunes DE, Ura S, et al. (2019). Cytokine profiles associated with erythema nodosum leprosum and type 1 reactions in leprosy patients. *Clinical Immunology*. 203: 61–67.
- Darlong, J. (2021) ‘Self-care in leprosy at the front line’, *Leprosy Review*, 92(4), pp. 356–365.
- Das, M., David, D., Horo, I., Van Hooij, A., Tió-Coma, M., Geluk, A., & Vedithi, S. C. (2023). Mycobacterium leprae and host immune transcriptomic signatures for reactional states in leprosy. *Frontiers in Microbiology*, 14.
- de Freitas, L.C., et al. (2018) ‘Innate immune responses in leprosy’, *Frontiers in Immunology*, 9, 518.
- de Jong, J.M.A. and de Vries, P.J. (2024) ‘Pharmacokinetics and pharmacodynamics of systemic corticosteroids in autoimmune and inflammatory diseases’, *Clinical Pharmacokinetics*, 63(4), pp. 345–361. doi:10.1007/s40262-024-01419-7.
- Dewi, D. A. R., Djatmiko, C. B. P., Rachmawati, I., Arkania, N., Wiliantari, N. M., & Nadhira, F. (2023). Immunopathogenesis of Type 1 and Type 2 Leprosy Reaction: An Update Review. *Cureus*. <https://doi.org/10.7759/cureus.49155>
- de Sabbata, K., Rodrigues, P., Almeida, S., and Fernandes, T., 2021. *Host-related laboratory parameters for leprosy reactions*. *Frontiers in Medicine*, 8, p.694376.
- Dupnik, K.M., Bair, T.B., Maia, A.O., Moraes, M.O., Sarno, E.N. & Modlin, R.L. (2015) ‘Transcriptional changes that characterize the immune reactions of leprosy’, *The Journal of Infectious Diseases*, 211(10), pp. 1658–1668.
- Eid, D., Franco-Paredes, C., Martinez, D.A. and Rosso, F. (2021) *Leprosy: Clinical presentations and disability outcomes*. *Clinical Infectious Diseases*, 73(4), pp. e815–e822.
- Ferreira, H., Leal-Calvo, T., Mendes, M.A., Avanzi, C., Busso, P., Benjak, A., Sales, A.M., Ferreira, C.P., de Berrêdo-Pinho, M., Cole, S.T., Sarno, E.N., Moraes, M.O. & Pinheiro, R.O. (2022) ‘Gene expression patterns associated with multidrug therapy in multibacillary leprosy’, *Frontiers in Cellular and Infection Microbiology*, 12, 917282.
- Fonseca, A.B. de L., Simon, M.V., Cazzaniga, R.A., de Moura, T.R., de Almeida, R.P., Duthie, M.S., Reed, S.G. & de Jesus, A.R. (2017) ‘The influence of innate and adaptive immune responses on the differential clinical outcomes of leprosy’, *Infectious Diseases of Poverty*, 6:5.
- Foss, N.T. (2020) ‘Erythema nodosum leprosum’, *Leprosy Review*, 91, pp. 1–10.
- Galeano, J., Contreras, A., Pabón, L. & Arboleda, M. (2023) ‘Necrotizing erythema nodosum as a manifestation of lepromatous leprosy relapse 50 years after the initial infection’, *The American Journal of Tropical Medicine and Hygiene*, 109(1), p. 53.
- Gama, R.S., Souza, M.L.M.d., Sarno, E.N., Moraes, M.O.d., Gonçalves, A., Stefani, M.M.A. et al. (2019) ‘A novel integrated molecular and serological analysis method to predict new cases of leprosy amongst household contacts’, *PLOS Neglected Tropical Diseases*, 13(6), e0007400.

- Garbin, C.A.S., Garbin, A.J.I., Carloni, M.E.O., Rovida, T.A.S. and Martins, R.J. (2016) 'The stigma and prejudice of leprosy: influence on the human condition', *Revista da Sociedade Brasileira de Medicina Tropical*, 48(2), pp. 194–201.
- Geluk A, Tió-Coma M, van Hooij A (2020). Biomarkers for leprosy: would you prefer T (cells)? *Leprosy Review*. 91(3): 300–312.
- Gonzales-Rospigliosi, C., De La Cruz-Vargas, J.A., Gómez, H., Talavera, J.E., Córdova Salazar, A.A. and Pichardo-Rodriguez, R. (2025) *Prognostic relevance of inflammatory cytokines IL-6 and TNF-alpha in patients with breast cancer: a systematic review and meta-analysis*, *Current Oncology*, 32(6), p.344.
- Gracino, M. E., Santos, B. M. dos, Garbelin, M. V., Nishi, V., Silva, D., Kondo, R. N., & Mariano, R. D. (2020). Leprosy: A systematic review. *International Journal of Dermatology Sciences*, 2(1), 08–21. <https://doi.org/10.33545/26649772.2020.v2.i1a.10>
- Hamzah, A. and Samsudin, R. (2025). Immunological complications in multibacillary leprosy with emphasis on type 2 reactions (ENL). *Indonesia Journal of Tropical Medicine*, 12(1), pp.44–53.
- Hector, L., Ramirez, P. and Gomez, R., 2023. Triggering factors of erythema nodosum leprosum: A multifactorial review. *International Journal of Dermatology and Immunology*, 11(2), pp.88–96.
- Hector, L., Santos, D. and Marquez, J., 2024. Recurrence patterns of erythema nodosum leprosum in lepromatous leprosy: A longitudinal cohort analysis. *Journal of Leprosy and Mycobacterial Diseases*, 9(1), pp.15–24.
- Huang, C. Y., Su, S. Bin, & Chen, K. T. (2024). An update of the diagnosis, treatment, and prevention of leprosy: A narrative review. In *Medicine (United States)* (Vol. 103, Issue 34, p. e39006). Lippincott Williams and Wilkins.
- Hulley SB, Cummings SR, Browner WS, Grady DG, Newman TB (2013). *Designing Clinical Research*. 4th ed. Philadelphia: Lippincott Williams & Wilkins.
- Hungria EM, Bühner-Sékula S, Oliveira RM, Aderaldo LC, Pontes MAA, Cruz R, et al. (2018). Leprosy reactions: the predictive value of Mycobacterium leprae-specific serology evaluated in a Brazilian cohort of leprosy patients (U-MDT/CT-BR). *PLoS Neglected Tropical Diseases*. 12(2): e0006230.
- Jang, Y.H., Choi, E.Y., Lee, H., Woo, J., Park, S., Noh, Y., Jeon, J.Y., Yoo, E.Y., Shin, J.Y. and Lee, Y.W. (2024) 'Long-term use of oral corticosteroids and safety outcomes for patients with atopic dermatitis', *JAMA Network Open*, 7(7), e2423563.
- Kahawita, I.P., Walker, S.L. and Lockwood, D.N.J. (2008) 'Tumour necrosis factor- α and erythema nodosum leprosum', *Clinical and Experimental Immunology*, 154(2), pp. 233–240.
- Kementerian Kesehatan Republik Indonesia (2025). Profil Kesehatan Indonesia Tahun 2024. Jakarta: Kementerian Kesehatan Republik Indonesia.
- Kindt TJ, Goldsby RA, Osborne BA (2017). *Kuby Immunology*. 8th ed. New York: W.H. Freeman and Company.

- Kurniasari, D., Putra, A. and Lestari, N. (2025). Clinical manifestations and disability burden of erythema nodosum leprosum in multibacillary patients. *Asian Pacific Journal of Tropical Dermatology*, 7(1), pp.41–50.
- Lee, J.H. and Kim, S.Y. (2023) ‘Tumor necrosis factor- α and innate immune responses in inflammatory diseases’, *International Journal of Molecular Sciences*, 24(7), pp. 1120–1135.
- Lemeshow S, Hosmer DW Jr, Klar J, Lwanga SK (1997). *Besar Sampel dalam Penelitian Kesehatan*. Yogyakarta: Gadjah Mada University Press.
- Lima, F.R., Silva, M.B., Costa, R. et al. (2022) ‘Bacilloscopy and polymerase chain reaction of slit-skin smear and dermal scrapings in Hansen’s disease: a cross-sectional study’, *Frontiers in Medicine*, 9, 972244.
- Lockwood, D.N.J. (2008) ‘Leprosy reactions’, *Current Opinion in Infectious Diseases*, 21(2), pp. 154–159.
- Lockwood DNJ, Saunderson P (2018). Nerve damage and reactions in leprosy. In: Scollard DM, Gillis TP, editors. *International Textbook of Leprosy*. Greenville: American Leprosy Missions.
- Lockwood, D.N.J., de Barros, B., Negera, E., Gonçalves, H., Hay, R.J., Kahawita, I.P., Singh, R.K., Kumar, B., Lambert, S.M., Pai, V.V., Penna, G.O., Prescott, G., de Arquer, G.R., Talhari, S., Srikantam, A., Walker, S.L. (2021) ‘Leprosy post-exposure prophylaxis risks not adequately assessed’, *The Lancet Global Health*, 9(4), pp. e400–e401.
- Lockwood, D.N.J., Penna, G.O., Lambert, S., Pai, V.V. & Walker, S.L. (2022) ‘Safer and newer antimicrobial drugs for leprosy – time to test monthly ROM in an adequately powered randomised trial?’, *Leprosy Review*, 93(2), pp. 96–101.
- Lubis, R.R., Agusni, I., Sjamsoe-Daili, E. and Mulianto, R. (2022) ‘Clinical characteristics and inflammatory markers in patients with erythema nodosum leprosum’, *Leprosy Review*, 93(2), pp. 123–131.
- Luo, Y., Kiriya, M., Tanigawa, K., Kawashima, A., Nakamura, Y., Ishii, N. and Suzuki, K. (2021) Host-related laboratory parameters for leprosy reactions, *Frontiers in Medicine*, 8: 694376.
- Mariana, A., Ansori, A.N.M., Fikri, F. and Widodo, E. (2022) ‘Leprosy cases and spatial distribution in endemic regions: a systematic review’, *Journal of Epidemiology and Global Health*, 12(2), pp. 123–131.
- Maymone, M.B.C., Venkatesh, S., Laughter, M., Abdat, R., Hugh, J., Dacso, M.M., Rao, P.N., Stryjewska, B.M., Dunnick, C.A. & Dellavalle, R.P. (2020) ‘Leprosy: Treatment and management of complications’, *Journal of the American Academy of Dermatology*, 83(1), pp. 17–30.
- Mehta, H., Jain, S., Narang, T., Chhabra, S. & Dogra, S. (2024) ‘Leprosy reactions: New knowledge on pathophysiology, diagnosis, treatment and prevention’, *Indian Journal of Dermatology, Venereology and Leprology*.
- Mendes, M.A., de Carvalho, D.S., Amadeu, T.P. and Pinheiro, R.O. (2022) ‘Innate immune responses in leprosy and their role in disease outcome’, *Frontiers in Immunology*, 13, pp. 1–12.
- Mitra, D.K. and Sadhu, S. (2018) ‘Emerging concepts of adaptive immunity in leprosy’, *Frontiers in Immunology*, 9, 604.

- Mulianto, R., Agusni, I., Sjamsoe-Daili, E. and van der Veen, M.H. (2008) 'Serum tumour necrosis factor- α levels in patients with erythema nodosum leprosum', *Leprosy Review*, 79(3), pp. 277–284.
- Murali, S., Vidyasagar, S., Manavalan, S. and Lakshminarasimhan, S. (2024) 'Steroid withdrawal syndrome: a masquerading clinical challenge', *Journal of Clinical & Scientific Research*, 13(3), pp. 228–230.
- Naafs, B., & van Hees, C. L. M. (2016). Leprosy type 1 reaction (formerly reversal reaction). *Clinics in Dermatology*, 34(1), 37–50. <https://doi.org/10.1016/j.clindermatol.2015.10.006>
- Narang T, Kumar B, Dogra S, Kamat D, Vinay K, Saikia UN (2020). Clinical predictors and outcome of erythema nodosum leprosum: a prospective study from a tertiary care center. *International Journal of Dermatology*. 59(11): 1365–1371.
- Narang T, Vinay K, Dogra S (2022). Erythema nodosum leprosum: A review of current management and emerging therapeutic options. *American Journal of Clinical Dermatology*. 23(5): 655–672.
- Nath, I. (2016) 'Immunopathogenesis of Leprosy: A Model for T Cell Anergy', *European Medical Journal – Dermatology*, 4(1), pp. 95–101.
- Nayak, R., Pradhan, S., Mohanty, P. and Sahu, B. (2023). Humoral immune responses and neutrophil-mediated inflammation in type 2 lepra reaction: A comprehensive review. *International Journal of Leprosy and Mycobacterial Research*, 5(1), pp.30–39.
- Negera, E., Bobosha, K., Walker, S. L., Endale, B., Howe, R., Aseffa, A., Dockrell, H. M., & Lockwood, D. N. (2017). New insight into the pathogenesis of erythema nodosum leprosum: The role of activated memory T-cells. *Frontiers in Immunology*, 8(SEP). <https://doi.org/10.3389/fimmu.2017.01149>
- Negera, E., et al. (2018) *perubahan immunophenotype T-cells pada reaksi tipe II erythema nodosum leprosum*, In: *Leprosy Classification, Clinical Features, Epidemiology, and Host Immunological Responses: Failure of Eradication in 2023*.
- Patel, V., Ahuja, R., Arava, S. K., Khandpur, S., Bhari, N., Gupta, V., & Ramam, M. (2024). A Retrospective Study of the Histopathological Spectrum of Erythema Nodosum Leprosum. *Indian Dermatology Online Journal*, 15(5), 779–786.
- Penna, G.O., Bühner-Sékula, S., Kerr, L.R.S., Stefani, M.M.A., Rodrigues, L.C., de Araújo, M.G., ... & Lastória, J.C. (2017) 'Uniform multidrug therapy for leprosy patients in Brazil (U-MDT/CT-BR): results of an open label, randomized and controlled clinical trial among multibacillary patients', *PLoS Neglected Tropical Diseases*, 11(7), e0005725.
- Polycarpou, A., Walker, S.L. & Lockwood, D.N.J. (2017) 'A systematic review of immunological studies of erythema nodosum leprosum', *Frontiers in Immunology*, 8:233.
- Prevedello, F.C. et al. (2017) 'Factors associated with leprosy: a case–control study in Espírito Santo, Brazil', *Revista do Instituto de Medicina Tropical de São Paulo*, 59, e65.

- Ploemacher, T., Faber, W.R., Menke, H., Rutten, V. and Pieters, T. (2020) *Reservoirs and transmission routes of leprosy: A systematic review*. PLOS Neglected Tropical Diseases, 14(4), e0008276.
- Roberta, J., Marcela, A., Daniel, S. and Paulo, R. (2022) 'Burden of leprosy and its impact on quality of life: a systematic review', *PLoS Neglected Tropical Diseases*, 16(4), e0010348.
- Roberto, M., Alvarez, J. and Castillo, F., 2022. Immune complex-mediated mechanisms in type 2 lepra reactions: An updated immunopathology overview. *Clinical Infectious Dermatology*, 6(3), pp.112–120.
- Rosa, T.L.S.A., Leal-Calvo, T., Tavares, I.F., Mendes, M.A., Dias, A.A., Piauy, M.H.S., Barboza, M.F.S., Kapuscinski, M., Costa, F.M.R., Marques, M.A.M., Belone, A.F.F., Sales, A.M., Hacker, M.A., Berredo-Pinho, M.M., Belisle, J.T., Moraes, M.O. and Pessolani, M.C.V. (2024) 'Whole blood transcriptomics reveals the enrichment of neutrophil activation pathways during erythema nodosum leprosum reaction', *Frontiers in Immunology*, 15, 1366125.
- Roy, S., Dey, T., Ghosh, S. and Sengupta, U. (2021) 'Inflammatory cytokine imbalance in erythema nodosum leprosum', *Leprosy Review*, 92(1), pp. 45–54.
- Scollard, D.M., Adams, L.B., Gillis, T.P., Krahenbuhl, J.L., Truman, R.W. and Williams, D.L. (2006) 'The continuing challenges of leprosy', *Clinical Microbiology Reviews*, 19(2), pp. 338–381.
- Scollard, D.M., Adams, L.B., Gillis, T.P., Krahenbuhl, J.L., Truman, R.W. and Williams, D.L. (2015) 'The continuing challenges of leprosy', *Clinical Microbiology Reviews*, 28(2), pp. 338–381.
- Scollard, D. (2019) 'Leprosy research is a necessity', *Leprosy Review*, 90(3), pp. 232–236.
- Scollard, D.M. (2021) 'Occasional series of scientific tricks and tips: The best presentation of the meeting', *Leprosy Review*, 92(2), pp. 198–200.
- Serrano-Coll, H., Wan, E. L., Restrepo-Rivera, L., & Cardona-Castro, N. (2024). Leprosy reactions: Unraveling immunological mechanisms underlying tissue damage in leprosy patients. In *Pathogens and Disease* (Vol. 82). Oxford University Press.
- Silva, E.A., de Souza, V.N., Martins, A.C. and Pinheiro, R.O. (2019) 'Cytokine profile in patients with erythema nodosum leprosum', *Leprosy Review*, 90(1), pp. 45–53.
- Silva, C.A., Mendes, T., Oliveira, R., Santos, J. and Ribeiro, M. (2024) 'Cellular and molecular mechanisms in leprosy pathogenesis: current insights', *Frontiers in Immunology*, 15, 1234567.
- Smith, C., Jones, A., Brown, L. and Taylor, R. (2017). *Importance of the immune response to Mycobacterium leprae in the skin*. Biomedical Dermatology, 3, p.12.
- Smith, J.A., Lee, C.H. and Kumar, P. (2022) 'Cytokine networks in inflammatory responses: TNF- α and beyond', *Frontiers in Immunology*, 13, pp. 1–15.
- Sousa, J.R. de, Sotto, M.N. & Simões Quaresma, J.A. (2017) 'Leprosy as a complex infection: breakdown of the Th1 and Th2 immune paradigm in the immunopathogenesis of the disease', *Frontiers in Immunology*, 8, 1635.

- Stefani MMA, Guerra JG, Sousa ALM, Costa MB, Oliveira MLW, Martelli CMT, et al. (2019). Potential plasma markers of type 1 and type 2 leprosy reactions: a preliminary report. *BMC Infectious Diseases*. 19: 75.
- Sukanya, G., Manoharan, K., Logeswari, P. T., & Naidu, D. K. (2023). Leprosy and broken bacilli on slit skin smear. *QJM: An International Journal of Medicine*, 116(7), 545–546. <https://doi.org/10.1093/qjmed/hcad056>
- Tanojo, N., Damayanti, Utomo, B., Ervianti, E., Murtiastutik, D., Prakoeswa, C. R. S., & Listiawan, M. Y. (2022). Diagnostic Value of Neutrophil-to-Lymphocyte Ratio, Lymphocyte-to-Monocyte Ratio, and Platelet-to-Lymphocyte Ratio in the Diagnosis of Erythema Nodosum Leprosum: A Retrospective Study. *Tropical Medicine and Infectious Disease*, 7(3).
- Tavares, A.M.R., de Souza-Rezende, J.A., de Menezes Lima, B. & Barreto, J.G. (2021) ‘Epidemiological profile of leprosy in the state of Mato Grosso: a descriptive study’, *Einstein (São Paulo)*, 19.
- Teles RMB, Graeber TG, Krutzik SR, Montoya D, Schenk M, Lee DJ, et al. (2013). Type I interferon suppresses type II interferon-triggered human anti-mycobacterial responses. *Science*. 339(6126): 1448–1453.
- Rêgo, J.L., Santana, N.L., Aguiar, E.R., Queiroz, I.S., Carvalho, L.P., Machado, P.R.L. and Castellucci, L.C. (2020) ‘Serum immune markers as triggers of reactional episodes in multibacillary patients with leprosy’, *Leprosy Review*, 91(4), pp. 393–402.
- van Hooij, A., Fat, E.T.K., de Jong, D., Khatun, M., Soren, S., Chowdhury, A.S., Roy, J.C., Alam, K., Kim, J.-P., Richardus, J.H. & Geluk, A. (2021) ‘Prototype multi-biomarker test for point-of-care leprosy diagnostics’, *iScience*, 24(1), 102006.
- Wagenaar, I. et al. (2015) ‘The epidemiology of leprosy: a review’, *Clinical Dermatology*, 33(1), pp. 26–33.
- Walker, S.L., Lebas, E., Doni, S.N. and Lockwood, D.N.J. (2012) ‘The mortality associated with erythema nodosum leprosum in Ethiopia: a retrospective hospital-based study’, *PLoS Neglected Tropical Diseases*, 6(3), e1691.
- Walker SL, Lebas E, Doni SN, Lockwood DNJ, Lambert SM, Lambert J, et al. (2014). The mortality associated with erythema nodosum leprosum in Ethiopia: A retrospective hospital-based study. *PLoS Neglected Tropical Diseases*. 8(3): e2690.
- Walker, S.L., Sales, A.M., Butlin, C.R., Shah, M., Maghanoy, A., Lambert, S.M., Darlong, J., Nicholls, P.G., Pai, V.V., Balagon, M. and Lockwood, D.N.J. (2017) ‘A leprosy clinical severity scale for erythema nodosum leprosum: An international, multicentre validation study of the ENLIST ENL severity scale’, *PLoS Neglected Tropical Diseases*, 11(7), e0005716.
- Walker, S.L. (2020) ‘Leprosy reactions’, in *International Textbook of Leprosy*, eds. D.M. Scollard & T.P. Gillis, American Leprosy Missions, Greenville, SC, Part I Section 2, Chapter 2.2, pp. 1–30.
- Walker, S.L. and Lockwood, D.N.J. (2021) ‘Erythema nodosum leprosum’, *Leprosy Review*, 92, pp. 3–15.

- Wong, Z.Y. et al. (2024) 'Immunosuppression for adult steroid-dependent or frequently relapsing nephrotic syndrome: defining steroid dependence', *PLoS ONE*, 19(3), e0307981.
- World Health Organization. (2019). *Global leprosy update 2018: moving towards a leprosy-free world. Weekly Epidemiological Record*, 94(35), pp. 389–412. World Health Organization.
- World Health Organization. (2020). *Global leprosy (Hansen disease) update, 2019: time to step-up prevention initiatives. Weekly Epidemiological Record*, 95(36), pp. 417–440. World Health Organization.
- World Health Organization. (2022). *Global leprosy update 2022: status of endemic countries*. Geneva: World Health Organization.
- World Health Organization. (2023). *Global leprosy (Hansen's disease) update, 2022: progress towards interruption of transmission. Weekly Epidemiological Record*, 98(35), pp. 429–452. World Health Organization.
- World Health Organization (2024). *Global leprosy (Hansen disease) update, 2023: transmission interrupted in children? Weekly Epidemiological Record*. 99(36): 387–408.
- Wu, J. and Boggild, A.K. (2016) 'Clinical Pearls: Leprosy Reactions', *Journal of Cutaneous Medicine and Surgery*, 20(6), pp. 484–485.
- Zhang, Q.P., Li, G., Li, C. et al. (2020) 'Epidemiological situation of leprosy in a province in China: a long time to diagnosis and a high rate of deformity', *BMC Public Health*, 20, 1790.